Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX in Advanced Refractory Thyroid Cancer
NCT02472080Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2016
- Primary completion
- Apr 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in Differentiated Thyroid Cancer (DTC), sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2016; status: terminated.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
Differentiated Thyroid Cancer (DTC)
Beyond the preview
Go deeper on NCT02472080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472080.